Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.…
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Oculis Holding (NASDAQ: OCS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 7.060 USD on 20 November 2026, down 63.6% over 52 weeks. Its 52-week range is 6.780 USD to 34.47 USD: the price is 79.5% below the high and 4.1% above the low.
Its market capitalisation is 393.35M USD.
Oculis Holding reports return on equity of -50.5% and revenue down 97.1% year over year.
It holds more cash than debt, a net cash position of 207.51M CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 2 March 2027.